KR20230030154A - Pharmaceutical composition for the prevention or treatment of colorectal cancer containing the extract of Tribonema species - Google Patents

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating colorectal cancer by inducing apoptosis using a water-soluble extract isolated from Tribonema sp., a type of yellow-green algae, wherein the water-soluble extract of Tribonema sp. has excellent anticancer activity, such as causing cytotoxicity or inducing apoptosis in colon cancer cells, thereby being usefully used as a pharmaceutical composition for preventing and treating colon cancer, a health functional food for preventing and alleviating colon cancer, and a health functional food for inhibiting metastasis of colon cancer.

Description

Pharmaceutical composition for the prevention or treatment of colorectal cancer containing the extract of Tribonema species}

The present invention relates to a pharmaceutical composition for preventing or treating colorectal cancer containing an extract of Tribonema sp. It relates to a pharmaceutical composition for preventing or treating colorectal cancer.

Pathologically, most colon cancers are adenocarcinomas, and they are largely divided into colon cancer and rectal cancer by site. The frequency of occurrence by site is the highest at about 50% in the lower large intestine, that is, the rectum. According to recent research results, colorectal cancer is a terrible cancer that ranks second in incidence and third in mortality among all cancers in Korea. It is increasing.

Although the cause of colorectal cancer is still unclear, genetic factors, dietary habits related to intake of high-fat and low-fiber foods, and inflammatory bowel disease are being considered. Colorectal cancer can occur in all age groups, but the incidence increases with age, and it often occurs in people in their 50s and 60s. The male-to-female incidence rates are slightly higher for colon cancer in women and rectal cancer in men.

Treatment of colorectal cancer is based on surgical resection, followed by chemotherapy and radiation therapy. Despite advances in surgical therapy, chemotherapy, and radiotherapy, colorectal cancer is known to have a high mortality rate when diagnosed after metastasis to other organs due to the nature of colorectal cancer, which progresses without specific symptoms, and misses the point of surgery. It is known that the 5-year average survival rate is 90% or more for stage 1, 70% or more for stage 2, 50% or more for stage 3, and 5% or less for stage 4. It can be seen that the survival rate increases markedly with treatment.

Current colorectal cancer treatments include oropyrimidine drugs such as 5-fluorouracil and capecitabine. Although these drugs have high anticancer effects, they also have serious side effects such as nausea, vomiting, stomatitis, diarrhea, anorexia, dermatitis, and hair loss.

Therefore, it is required to develop new anticancer drugs with significantly low side effects in addition to high anticancer effects. In particular, efforts are being made to develop new targeted therapies with high selectivity that selectively attack only colon cancer cells, not normal cells. Developing such therapeutic substances requires the discovery of substances that selectively attack molecular pathways that are important for survival and growth specifically for colorectal cancer.

An example of such a technique is disclosed in the following documents and the like.

For example, in Patent Document 1 below, an omega-7 fatty acid composite made from yellow-green algae obtained by heterotrophic culture and/or mixed nutrient culture of Tribonema and yellow-green algae obtained by heterotrophic culture and/or mixed nutrient culture As a method of culturing, a technique in which the content of omega-7 fatty acids in the omega-7 fatty acid composition is 30% to 70% is disclosed.

In addition, Patent Document 2 below discloses a method for producing tribonema biological oil that mass-produces omega-7 fatty acids by culturing tribonema, a method for producing tribonema biological oil prepared through the method, and a product prepared from tribonema biological oil. Technologies relating to biodiesel, aviation kerosene, food or feed are disclosed.

On the other hand, Non-Patent Document 1 below reports that the sulfated polysaccharide isolated from Tribonema has immunomodulatory and anticancer effects, and the cancer types used for anticancer evaluation were blood cancer (Raw293 cells) and liver cancer (HepG2) cells. It is limited, and the apoptosis-inducing effect of tribonema-derived sulfated polysaccharide is disclosed for a technology in which the key to anticancer effect is disclosed.

Australian Patent Publication AU2016399463C1 (published on June 20, 2019) Chinese Patent Publication CN103960117A (published on August 6, 2014)

Partial Characterization, the Immune Modulation and Anticancer Activities of Sulfated Polysaccha-rides from Filamentous Microalgae Tribonema sp.(Mmolecules, Pengcheng Li, 2019)

As described above, Patent Documents 1 and 2 disclose a technology for mass-producing omega-7 fatty acids by applying tribonema, but the anticancer effect of a water-soluble extract of tribonema by inducing apoptosis is not disclosed.

On the other hand, although the technology disclosed in Non-Patent Document 1 applies the sulfated polysaccharide isolated from Tribonema, the anticancer drug development process using the entire water-soluble extract is not disclosed, and the anticancer efficacy against colon cancer cells is also disclosed. There wasn't.

An object of the present invention has been made to solve the problems described above, and to provide a pharmaceutical composition for preventing and treating colorectal cancer containing a water-soluble extract of Tribonema species, which is a yellow-green algae, as an active ingredient.

Another object of the present invention is to provide a health functional food for preventing and improving colorectal cancer containing a water-soluble extract of Tribonema species, a yellow-green algae, as an active ingredient.

Another object of the present invention is to provide a health functional food for inhibiting metastasis of colorectal cancer containing a water-soluble extract of Tribonema species as an active ingredient.

In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating colorectal cancer containing an extract of Tribonema sp., a yellow-green algae, as an active ingredient.

In addition, in the composition, the extract of the yellow-green algae Tribonema species is characterized in that it is extracted using water as a solvent.

In addition, the extract of Tribonema species, which is a yellowish green algae, is obtained by (a) drying Tribonema and adding distilled water, (b) crushing using a pestle in succession to the above step (a), and then using ultrasonic waves. (c) centrifuging the algae crushed in step (b) at 4° C. and 13,000 rpm for 15 minutes to remove debris and obtaining a supernatant; (d) Filtering the supernatant obtained in step (c) with a 0.02 μm syringe filter to maintain the extract in a sterile state, (e) using a rotary vacuum evaporator for the extract maintained in a sterile state in step (d) It is characterized in that it is extracted by evaporating the solvent and concentrating the concentration 10 times.

In addition, the extract of Tribonema species, which is a yellow-green algae, is characterized in that it inhibits the activity of ERK (Extracellular signal-regulated kinase) enzyme, which is a key signaling molecule for cell growth.

On the other hand, in order to achieve the above object, the present invention provides a health functional food for preventing and improving colorectal cancer containing an extract of Tribonema sp., a yellow-green algae, as an active ingredient.

In addition, in order to achieve the above object, the present invention provides a health functional food for inhibiting metastasis of colorectal cancer containing an extract of Tribonema sp., a yellow-green algae, as an active ingredient.

As described above, according to the pharmaceutical composition for preventing or treating colorectal cancer containing the Tribonema sp. extract according to the present invention, the Tribonema sp. water-soluble extract exhibits cytotoxicity against colon cancer cells. Since it has excellent anticancer activity such as causing or inducing cell death, it can be usefully used as a pharmaceutical composition for preventing and treating colorectal cancer, a health functional food for preventing and improving colorectal cancer, and a health functional food for inhibiting metastasis of colorectal cancer. effect is obtained.

1 is a view showing the cytotoxicity of the water-soluble extract of Tribonema according to the present invention selectively against human colon cancer cells other than breast cancer cells or normal lymphocyte cells;
Figure 2 is a photograph showing that the human colon cancer cytotoxicity process by the water-soluble extract of Tribonema according to the present invention is not due to apoptosis;
Figure 3 is a photograph showing that the Tribonema water-soluble extract according to the present invention inhibits the activity of the ERK enzyme, a key growth regulator molecule, in the treated human colon cancer cells, while having no effect on the apoptosis enzyme, caspase-3;
Figure 4 is a photograph showing that the human colorectal cancer cytotoxicity process by the water-soluble extract of Tribonema according to the present invention is due to cell necrosis rather than cell death.

The above and other objects and novel features of the present invention will become more apparent from the description of this specification and accompanying drawings.

The term "extract" used in the present invention is meant to be commonly used as a crude extract in the field of application to the technology of the present invention, but also includes fractions obtained by additional fractionation of the extract in a broad sense. That is, the Tribonema sp. extract according to the present invention may include not only those obtained using the above-described extraction solvent, but also those obtained by additionally applying a purification process thereto. For example, a fraction obtained by passing an extract through an ultrafiltration membrane having a certain molecular weight cut-off value, separation by various chromatography (designed for separation according to size, charge, hydrophobicity or affinity), etc. Fractions obtained through various purification methods may also be included in the extract of the present invention.

In addition, the Tribonema species extract used in the present invention may be prepared in a powder state by additional processes such as distillation under reduced pressure and freeze drying or spray drying.

In addition, the term "contained as an active ingredient" used in the present invention means containing an amount sufficient to achieve the efficacy or activity of the Tribonema species extract.

On the other hand, since the present invention is a composition extracted from Tribonema species, which is a natural plant material, and there is no side effect on the human body even when administered in an excessive amount, the upper limit of the amount of the Tribonema species extract included in the composition of the present invention is selected within an appropriate range by those skilled in the art. can be carried out.

In addition, unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by a person skilled in the art to which the present invention belongs.

First, the outline of this invention is demonstrated.

New anticancer agents from natural products have been developed over the past decades (Kato et al., Oncoscience 2: 576-80, 2015; Vazquez et al., BMC Syst Biol. 7:31, 2013). According to the Pharmaceutical Research and Manufacturers of America, more than 800 anticancer drugs derived from natural products including plants and microorganisms have been reported. It is known to be effective in various types of cancer such as prostate cancer, breast cancer, lung cancer and colon cancer (Basmadjian et al., Front Chem. 2:20 2014; Sawadogo et al., Molecules 20: 7097-7142, 2015; Orang- Ojong et al., Mol Clin Oncol. 1:610-620, 2013; Ko et al., Curr Med Chem. 21:2346-2356, 2014; Giddings et al., J Ind Microbiol Biotechnol.40:1181-1210; 2013).

Algae are unicellular photosynthetic eukaryotes (Gimpel et al., Font Microbiol.6:1376, 2015; Sharma et al., Environmental reviews 19:1-15, 2011). It is known that secondary metabolites of algae exhibit various compatibility. Recent studies have shown that algae extracts play a significant role in the pharmaceutical industry (Martins et al., Mar Drugs 12: 1066-1101, 2014; Dias et al., Metabolites 2: 303-336, 2012; David et al., Phytother Res. 14:299-315, 2015). Algae-derived compounds have been reported to have anticancer activity through the regulation of multiple mechanisms, such as cytotoxicity, inhibition of invasion, and promotion of apoptosis in cancer cells (Lee et al., Cancer Cell Int. 13:55, 2013; Farooqi et al., Cancer Cell Int. 12:50, 2012). Fucoxanthin found in algae is known to reduce the growth of cancer cells by stopping cancer suppressor genes and cell cycle without inducing apoptosis (Takahashi et al., Oncol Lett. 10: 1463-1467, 2015; Peng et al. , Mar Drugs 9:1806-1828, 2011).

In particular, the anticancer effect of algae-derived substances has attracted attention in relation to the treatment of various human carcinomas. Accordingly, the present inventors sought to find a new algae-derived substance exhibiting anticancer activity and to develop a potential anticancer agent using the same. That is, in the present invention, the anticancer effect on human colorectal cancer cells was confirmed using the tribonema extract. It was confirmed that the water-soluble extract of Tribonema sp., a yellow-green algae, exhibited cytotoxicity against colon cancer cells and even induced apoptosis.

Through this, it was confirmed that the water-soluble extract of Tribonema species has excellent anticancer activity against colorectal cancer, and the present invention was completed.

In the present invention, it was first reported that the yellow-green algae, Tribonema, can exhibit anticancer effects in human colorectal cancer cells. Specifically, as shown in (B) and (D) of FIG. 1, the water-soluble extract of Tribonema was prepared from breast cancer cells (MDA231), which is another carcinoma, and peritoneal lymphocytes (B cells and peritoneal T cells), which are normal cells isolated from mice. cells) was not cytotoxic. 1 is a diagram showing the cytotoxicity of the water-soluble extract of Tribonema according to the present invention selectively against human colon cancer cells other than breast cancer cells or normal lymphocyte cells.

However, as shown in (A) of FIG. 1, it showed high cytotoxicity against human colon cancer cells. In general, when cells undergo apoptosis or necrosis, they change morphologically (Elmore et al., Toxicol Pathol 35: 495-516, 2007; Saraste et al., Cardiovasc Res. 45: 528-537, 2000). That is, when apoptosis or necrosis proceeds, the cell shape is contracted or deformed, and is different from the existing cell shape. In addition, the size becomes smaller or the cytoplasm becomes denser.

In the present invention, as shown in (C) of FIG. 1, the cells treated with the Tribonema extract were confirmed to have a contracted, round shape rather than the shape of existing cancer cells. Taken together, as shown in Figure 1, it shows that the water-soluble extract of Tribonema can exhibit a selective anticancer effect against colon cancer cells.

The process of apoptosis depends on the activation of proteases such as caspases-3 that degrade proteins (Aijl et al., Mutat Res. 728: 23-34, 2011). Therefore, the degree of caspase-3 activation in relation to the apoptosis pathway was measured at the protein level. However, as shown in FIGS. 2 and 3 , the water-soluble extract of Tribonema failed to induce apoptosis and activation of caspase-3. Figure 2 is a photograph showing that the process of human colon cancer cytotoxicity by the water-soluble extract of Tribonema according to the present invention is not due to cell death, and Figure 3 is a human colon cancer treated with the water-soluble extract of Tribonema according to the present invention. This photo shows that while inhibiting the activity of the ERK enzyme, a key growth regulator molecule in cells, there is no effect on caspase-3, a cell death enzyme.

In addition, as shown in FIG. 3, it was also confirmed that the treatment with the tribonema-soluble extract lowered the activity of ERK (Extracellular signal-regulated kinase) enzyme, a key signaling molecule for cell growth.

The above results show that cytotoxicity was strongly induced by lowering survival signals in cells. Finally, whether or not apoptosis was induced was confirmed. Unlike apoptosis, which proceeds as a cell's own suicide program, necrosis refers to cell death caused by physical trauma or various types of toxic substances, and the extent of cell membrane damage can be confirmed through PI staining. (Tonnus W, Meyer C, Linkermann A., J. Pathol., 247 (5): 697-707, 2019).

As a result of the experiment, as shown in FIG. 4 , it was confirmed that treatment with the tribonema-soluble extract induces apoptosis through cell membrane damage to human colon cancer cells. Figure 4 is a photograph showing that the human colon cancer cytotoxicity process by the water-soluble extract of Tribonema according to the present invention is due to cell necrosis, not cell death.

In summary, the present invention showed that treatment with a water-soluble extract of Tribonema, a yellow-green algae, induced apoptosis in colorectal cancer cells in vitro. We provide evidence that treatment with tribonema extract can act as a novel anticancer agent because it can cause cytotoxicity to colorectal cancer cells as well as induce apoptosis.

Therefore, the present invention can provide a pharmaceutical composition for preventing or treating colorectal cancer, a health functional food for preventing and improving colorectal cancer, and a health functional food for inhibiting metastasis of colorectal cancer, which contain tribonema extract as an active ingredient. .

In the present invention, the tribonema extract is preferably extracted using water as a solvent, and apoptosis induces apoptosis through cell membrane deformation, and inhibition of the activity of ERK-1/2 enzyme among signaling molecules in cells can also be achieved. there is.

Hereinafter, the present invention will be described in more detail through examples. These examples are only for exemplifying the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not to be construed as being limited by these examples.

[Example 1]

1-1. Algae collection and extract preparation

Tribonema sp., a kind of yellow-green algae used in the present invention, was collected from fresh water near Pocheon. 10 g of dried yellow-green algae, Tribonema, was stored in a 50 ml tube, and 10 ml of tertiary distilled water was added thereto. After crushing using a pestle, the algae were additionally completely crushed using ultrasonic waves.

Thereafter, the residue was removed by centrifugation at 13,000 rpm for 15 minutes at 4° C., and the supernatant was obtained, and the extract was maintained in a sterile state by filtering with a 0.02 μm syringe filter. Then, the solvent was evaporated from the extract using a rotary vacuum evaporator at a temperature of 55 ° C., and the concentration was concentrated 10 times, and the remaining extract obtained was used in Examples.

1-2. Cytotoxicity evaluation of Tribonema sp. extracts on colon cancer cells

The cytotoxic effect according to the present invention was evaluated using the MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay. . Cells were seeded in a 96-well plate at a density of 1×10 3 cells/well and incubated at 37° C. with 5% CO ₂ . Cell survival was measured using MTS. Human colon epithelial cells having a confluency of 90% were treated with the tribonema extract at each concentration for 48 hours, and then 20 μl of MTS was added to detect metabolically active cells.

Incubated for 1 hour and analyzed on a Multilabel Counter (Bio-Rad Laboratories). When compared to the control group, it was confirmed that treatment with tribonema extract lowered the health of colon epithelial cells by nearly 71%. Cytotoxicity was concentration-dependent. However, it was confirmed that there was no cytotoxicity in MDA-231 cells, which are breast cancer cells. In addition, it was confirmed that cytotoxicity did not appear even when tribonema extract was treated with peritoneal lymphocytes (B cells, T cells), which are normal cells isolated from the abdominal cavity of mice. This shows that the tribonema extract is selectively toxic to human colorectal cancer cells.

1-3. Evaluation of cell morphological transformation of tribonema extract on colorectal cancer cells

A sterilized cover glass was placed on a 6-well plate, human colon cancer cells were seeded thereon at a density of 1 x 10 ³ cells/well, and incubated at 37°C with 5% CO ₂ .

Then, the tribonema extract was treated for 48 hours by concentration, and fixed at 4° C. with formalin. Next, it was observed under an optical microscope and morphological changes were evaluated. In the control group, the typical human colon epithelial cell morphology was observed. Like epithelial cells, many cells grow together and show a large cell mass due to the form attached to the bottom. In contrast, in the cells treated with the Tribonema extract, the bottom attachment was reduced, and they were round in shape and were observed as cells of a smaller size than the original cells, indicating that cytotoxicity was in progress.

[Example 2]

In Example 2, TUNEL analysis was applied.

For apoptosis analysis, the apoptotic effect of the tribonema extract according to the present invention was evaluated using the TUNEL kit (BD Biosciences).

A sterilized cover glass was placed on a 6-well plate, human colon cancer cells were seeded thereon at a density of 1 x 10 3 cells/well, and incubated at 37°C with 5% CO ₂ . Then, 10 μl of the tribonema extract was treated and cultured for 48 hours. After that, it was fixed at 4 ℃ with formalin. After washing the cells twice with cold PBS (phosphate buffered saline), TUNEL staining was performed.

After adding an appropriate amount of enzyme and fluorescent nucleic acid, the mixture was reacted at room temperature for 3 hours. Then, the cells were washed twice with cold PBS, and permanent specimens were prepared using mounting solution. Double staining was performed in parallel with PI (Propidium Iodide) staining to confirm the location of the cells. All of these processes were conducted in a dark room.

Then, using a fluorescence microscope, it was confirmed whether DNA, which is an apoptosis marker, was cut. In the control group, almost no DNA cleavage stained green was observed. Contrary to expectations, no green dots were observed even in the cells treated with the Tribonema extract. Considering that the green fluorescence is DNA cleavage, the cytotoxicity of the tribonema extract is independent of apoptosis.

[Example 3]

In Example 3, Western blot was applied.

When toxicity appeared in human colon epithelial cells by the stimulation of the Tribonema extract according to the present invention, changes in activity of key signaling molecules in the cells were evaluated. To this end, the tribonema extract was divided into 24 hours and 48 hours, and then the cells were treated with RIPA buffer (50 mM Tris Cl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 0.5% Nadeoxycholate). ) was dissolved in

Total protein (50 μg) from each sample was resolved on a 10-15% Criterion™ Tris-HCl pre-cast gel (BioRad) and transferred to a nitrocellulose membrane. The membrane was incubated at 4°C with a primary antibody (anti-caspase-3, Cell Signaling). After probing with HRP (Santa Cruz Biotechnology)-conjugated secondary antibody IgG, the membrane was developed with enhanced chemiluminescence (Amersham Pharmacia). The degree of activation of the ERK 1/2 molecule, which is a key molecule for cell growth, was also confirmed in the same manner. In particular, anti-phospho-ERK 1/2 antibody was used to detect activated ERK protein. As a result, it was confirmed that the activity of the ERK enzyme, which is important for cell growth, was lowered in human colon epithelial cells treated with the tribonema extract according to the present invention. However, as shown in FIGS. 2 and 3 , activation of caspase-3, an apoptosis promoting enzyme, was not observed. Summarizing the results, it was found that the stimulation of the water-soluble extract of Tribonema according to the present invention did not activate the apoptosis-related signal transduction pathway.

[Example 4]

In Example 4, PI (Propidium iodide) staining was applied.

The effect of necrosis by tribonema extract was evaluated using PI (sigma). A sterilized cover glass was placed on a 6-well plate, human colon cancer cells were seeded thereon at a density of 1 x 10 3 cells/well, and incubated at 37°C with 5% CO ₂ . In addition, 100 μl of the Tribonema extract according to the present invention was treated and cultured for 48 hours.

After that, it was fixed at 4 ℃ with formalin. After washing the cells twice with cold PBS, PI (1 μg/ml) was added and reacted at room temperature for 15 minutes. Then, the cells were washed 4 times with PBS, and permanent specimens were prepared using a mounting solution. Subsequently, it was confirmed whether the cell membrane was destroyed using a fluorescence microscope. Whole cell images were taken using an inverted microscope. In the control group, almost no cells stained red by PI were observed, indicating that the cell membrane is intact. However, in the cells treated with the water-soluble extract of Tribonema according to the present invention, a significant increase in red-stained cells was observed, which shows that there are many cells with severely destroyed cell membranes.

As shown in FIG. 4, considering that the red fluorescent staining is cell necrosis accompanied by cell membrane destruction, it shows that the cytotoxicity of the Tribonema extract according to the present invention is associated with cell necrosis.

The pharmaceutical composition of the present invention is prepared in unit dosage form by formulation using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily performed by those skilled in the art, or Or it can be prepared by incorporating into a multi-dose container. At this time, the formulation may be in the form of a solution, suspension, syrup or emulsion in an oil or aqueous medium, or may be in the form of an extract, powder, powder, granule, tablet or capsule, and may additionally contain a dispersing agent or stabilizer.

That is, the composition according to the present invention may further include pharmaceutically acceptable additives, wherein the pharmaceutically acceptable additives include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, and hydrogen phosphate. Calcium, Lactose, Mannitol, Taffy, Gum Arabic, Pregelatinized Starch, Corn Starch, Powdered Cellulose, Hydroxypropyl Cellulose, Opadry, Sodium Starch Glycolate, Carnauba Lead, Synthetic Aluminum Silicate, Stearic Acid, Magnesium Stearate, Aluminum Stearate , calcium stearate, white sugar, dextrose, sorbitol, and talc may be used. A pharmaceutically acceptable additive according to the present invention is preferably included in an amount of 0.1 to 90 parts by weight based on the composition, but is not limited thereto.

That is, the composition of the present invention can be administered in various oral and parenteral dosage forms during actual clinical administration. It can be prepared using Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and these solid preparations contain evergreen hazelnut fern fraction or a compound isolated therefrom and at least one or more excipients, for example, starch, calcium carbonate ( Calcium carbonate), sucrose, lactose, or gelatin may be mixed.

In addition to simple excipients, lubricants such as magnesium styrate and talc may also be used. Liquid formulations for oral use include suspensions, solutions for oral use, emulsions, and syrups. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. . Preparations for parenteral administration may include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. As a base for the suppository, witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogeratin and the like may be used.

In addition, the composition according to the present invention can be administered orally or parenterally depending on the desired method, and in the case of parenteral administration, external skin or intraperitoneal injection, intrarectal injection, subcutaneous injection, intravenous injection, intramuscular injection or intrathoracic injection It is preferable to select an injection injection method. The dosage can be applied in various ranges depending on the patient's weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and severity of the disease.

On the other hand, the present invention can provide a health functional food for preventing and improving colorectal cancer containing a water-soluble extract of yellow-green algae of the Tribonema species as an active ingredient.

In addition, the present invention can provide a health functional food for inhibiting metastasis of colorectal cancer containing a water-soluble extract of yellow-green algae of the Tribonema species as an active ingredient.

The health functional food according to the present invention may further include ingredients that are commonly added during food preparation and are acceptable in food science. For example, when it is prepared as a beverage, one or more components from citric acid, high fructose corn syrup, sucrose, glucose, acetic acid, malic acid, and fruit juice may be further included in addition to the water-soluble extract of yellow-green algae, which is a Tribonema species of the present invention.

The amount that can be included as an active ingredient in the health functional food according to the present invention can be appropriately selected according to the age, sex, weight, condition, and symptoms of disease of a person who wants to prevent and improve colorectal cancer or inhibit metastasis of colorectal cancer, and preferably It is recommended to include about 0.01 g to 10.0 g per day for adults, and by ingesting a health functional food having such a content, the effect of preventing and improving colorectal cancer or inhibiting colorectal cancer metastasis can be obtained.

Having described specific parts of the present invention in detail above, it will be clear to those skilled in the art that these specific descriptions are only preferred embodiments, and the scope of the present invention is not limited thereby. . Accordingly, the substantial scope of the present invention will be defined by the appended claims and their equivalents.

Claims (6)

A pharmaceutical composition for preventing or treating colorectal cancer containing an extract of yellow-green algae, Tribonema sp., as an active ingredient. In paragraph 1,
A pharmaceutical composition for the prevention or treatment of colorectal cancer, characterized in that the extract of the yellow-green algae Tribonema species is extracted using water as a solvent. In paragraph 1,
The extract of the yellow-green algae Tribonema species is
(a) drying tribonema and adding distilled water;
(b) crushing using a pestle continuously in step (a) and then completely crushing algae using ultrasonic waves;
(c) centrifuging the algae crushed in step (b) at 4° C. and 13,000 rpm for 15 minutes to remove debris and obtain a supernatant;
(d) maintaining the extract in a sterile state by filtering the supernatant obtained in step (c) with a 0.02 μm syringe filter;
(e) a pharmaceutical for preventing or treating colorectal cancer, characterized in that extracted by evaporating the solvent using a rotary vacuum evaporator for the extract maintained in a sterile state in step (d) and concentrating the concentration 10 times enemy composition. In paragraph 1,
A pharmaceutical composition for the prevention or treatment of colorectal cancer, characterized in that the extract of the yellow-green algae Tribonema species inhibits the activity of ERK (Extracellular signal-regulated kinase) enzyme, which is a key signaling molecule for cell growth. Health functional food for prevention and improvement of colorectal cancer containing extract of Tribonema sp., a yellow-green algae, as an active ingredient. A health functional food for inhibiting metastasis of colorectal cancer containing an extract of Tribonema sp., a yellow-green algae, as an active ingredient.

Images